Gwendolyn Wu
Senior Reporter | LinkedInGwendolyn Wu is a senior reporter at BioPharma Dive covering biotech startups, venture capital, IPOs and the ecosystem that supports them. She was selected as the 2024 McAllister Editorial Fellow by SIIA in recognition for her work on a series of stories examining the world’s first CRISPR medicine. Previously, she authored Bay Briefing, the San Francisco Chronicle’s flagship weekday newsletter, and covered COVID-19 and the business of healthcare for the Houston Chronicle. Outside of the newsroom, Gwendolyn teaches at the California Scholastic Press Association summer workshop for high school journalists, and has led student and early career programs for the Asian American Journalists Association. She has degrees in history and sociology from the University of California at Santa Barbara.
445 articles by Gwendolyn Wu
-
Boulevard starts up with $65M to pursue targeted autoimmune drugs
Aug. 12, 2026 -
Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
Aug. 11, 2026 -
Vaderis hauls in $152M to test an AKT-targeting drug
Aug. 11, 2026 -
Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
Aug. 10, 2026 -
With $263M, LifeMine unearths a new drug for organ transplants
Aug. 6, 2026 -
Cardiac drug developer Braveheart banks more than $382M in IPO
Aug. 5, 2026 -
A COPD drug from China draws $115M in venture funding
Aug. 5, 2026 -
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
July 30, 2026 -
Caldera, Vidya add to recent flurry of biotech mergers
July 29, 2026 -
An eye drug biotech banks $118M and stocks its executive suite
July 28, 2026 -
Sanofi halts development of troubled immune drug in eczema
July 24, 2026 -
Braveheart, Attovia join next wave of biotech IPOs
July 15, 2026 -
Judge orders Apple Tree partner to forfeit oversight of venture fund
July 14, 2026 -
Biotech startup funding gap widens despite rebound in VC investment
July 13, 2026 -
Gene editing developer Scribe plots an IPO
July 6, 2026 -
Cancer, immune drugmakers dominate VC funding so far in 2026
July 6, 2026 -
A PureTech startup banks $180M for a new IPF drug
July 2, 2026 -
Beeline ups its Series A round for immune drug work
June 30, 2026 -
At BIO, tension over China biotech deal regulation looms
June 26, 2026 -
Antares gets $105M from Novartis for new cancer drugs
June 25, 2026 -
‘The window’s open’: At BIO, investors take stock of a growing class of biotech IPOs
June 23, 2026 -
Bionyra brings in $165M for next-generation immune drugs
June 22, 2026 -
Kardigan extends biotech’s streak of big IPOs with $400M haul
June 17, 2026 -
Lilly buys non-opioid pain drugmaker 4E
June 16, 2026 -
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
June 11, 2026
